Your browser is no longer supported. Please, upgrade your browser.
Epizyme, Inc.
Index- P/E- EPS (ttm)-2.24 Insider Own0.20% Shs Outstand101.51M Perf Week0.82%
Market Cap1.27B Forward P/E- EPS next Y-2.15 Insider Trans0.47% Shs Float82.92M Perf Month-3.85%
Income-221.90M PEG- EPS next Q-0.59 Inst Own95.40% Short Float12.75% Perf Quarter-10.52%
Sales11.70M P/S108.49 EPS this Y-12.00% Inst Trans0.10% Short Ratio10.56 Perf Half Y-16.61%
Book/sh2.05 P/B5.98 EPS next Y4.40% ROA-52.70% Target Price- Perf Year-52.91%
Cash/sh2.70 P/C4.53 EPS next 5Y38.00% ROE-83.50% 52W Range9.90 - 27.82 Perf YTD12.80%
Dividend- P/FCF- EPS past 5Y-3.00% ROI-53.70% 52W High-55.97% Beta1.55
Dividend %- Quick Ratio8.70 Sales past 5Y-10.50% Gross Margin72.20% 52W Low23.74% ATR0.66
Employees203 Current Ratio8.90 Sales Q/Q-36.80% Oper. Margin- RSI (14)53.59 Volatility5.58% 5.45%
OptionableYes Debt/Eq0.00 EPS Q/Q-39.40% Profit Margin- Rel Volume1.35 Prev Close11.81
ShortableYes LT Debt/Eq0.40 EarningsNov 06 BMO Payout- Avg Volume1.00M Price12.25
Recom2.00 SMA204.15% SMA501.85% SMA200-13.98% Volume1,349,044 Change3.73%
Dec-21-20Downgrade Jefferies Buy → Hold $14
Apr-01-20Downgrade Oppenheimer Outperform → Perform
Mar-04-20Initiated Barclays Overweight $33
Feb-25-20Reiterated H.C. Wainwright Buy $25 → $36
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Dec-06-19Upgrade Morgan Stanley Equal-Weight → Overweight
May-30-19Resumed Citigroup Buy
Jan-07-19Upgrade Leerink Partners Mkt Perform → Outperform
Sep-07-18Resumed Morgan Stanley Equal-Weight
Jul-03-18Downgrade Leerink Partners Outperform → Mkt Perform
Jan-24-18Resumed Jefferies Buy $25
Jan-10-18Initiated Morgan Stanley Overweight $20
Nov-02-17Downgrade RBC Capital Mkts Outperform → Sector Perform $20 → $16
Sep-20-17Initiated Jefferies Buy $23
May-10-17Resumed RBC Capital Mkts Outperform $19 → $20
Apr-13-17Initiated Oppenheimer Outperform
May-10-16Reiterated Mizuho Buy $20 → $18
Apr-05-16Initiated Citigroup Buy $17
Mar-14-16Upgrade H.C. Wainwright Neutral → Buy $25
Mar-10-16Reiterated Wedbush Outperform $33 → $22
Dec-18-20 02:43PM  
Dec-06-20 11:30AM  
Nov-29-20 12:30PM  
Nov-16-20 05:16AM  
Nov-13-20 12:56PM  
Nov-11-20 04:05PM  
Nov-10-20 05:50AM  
Nov-09-20 10:16AM  
Nov-08-20 09:24AM  
Nov-06-20 07:31PM  
Oct-30-20 06:30AM  
Oct-28-20 12:33PM  
Oct-07-20 03:29PM  
Oct-02-20 09:21AM  
Sep-08-20 06:30AM  
Sep-03-20 11:31AM  
Aug-18-20 01:05PM  
Aug-05-20 11:29AM  
Aug-04-20 05:00PM  
Jul-28-20 06:30AM  
Jul-16-20 06:31PM  
Jun-28-20 09:31AM  
Jun-20-20 07:57AM  
Jun-19-20 10:19AM  
Jun-18-20 01:31PM  
Jun-17-20 01:56PM  
Jun-16-20 07:09AM  
Jun-03-20 11:30AM  
May-26-20 12:55PM  
May-14-20 09:22AM  
May-13-20 05:12PM  
May-07-20 10:51AM  
May-05-20 09:11AM  
May-04-20 07:00PM  
Apr-27-20 12:32PM  
Apr-26-20 10:02AM  
Apr-19-20 07:02AM  
Apr-08-20 06:56PM  
Mar-25-20 11:30AM  
Mar-20-20 06:30AM  
Mar-06-20 03:41AM  
Feb-26-20 06:39AM  
Feb-25-20 12:09PM  
Feb-24-20 07:45AM  
Feb-23-20 06:38PM  
Feb-20-20 08:42AM  
Feb-19-20 09:21AM  
Feb-18-20 06:30AM  
Feb-14-20 08:23AM  
Feb-12-20 06:55AM  
Feb-06-20 05:50PM  
Feb-05-20 11:52AM  
Jan-31-20 05:50PM  
Jan-29-20 09:59AM  
Jan-24-20 12:00PM  
Jan-23-20 06:07PM  
Jan-22-20 11:30AM  
Jan-21-20 09:26AM  
Jan-20-20 02:04PM  
Jan-17-20 08:45AM  
Jan-09-20 04:47PM  
Jan-08-20 12:00PM  
Jan-07-20 10:26AM  
Jan-06-20 06:30AM  
Dec-30-19 09:24AM  
Dec-26-19 10:38AM  
Dec-24-19 08:15AM  
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Agarwal ShefaliChief Medical OfficerDec 03Sale13.542,52234,14876,089Dec 07 07:00 AM
GOLDFISCHER CARLDirectorNov 11Buy12.075,00060,3505,000Nov 13 07:05 AM
Beaulieu JosephCorporate ControllerSep 02Sale12.885436,9945,958Sep 03 09:30 PM
MOTT DAVID MDirectorJun 26Buy16.0362,019994,16582,601Jun 26 07:12 PM
Beaulieu JosephCorporate ControllerJun 26Sale16.153175,1204,838Jun 30 09:04 AM
Bazemore Robert BPresident & CEOJun 26Sale16.154,77377,084250,098Jun 30 09:01 AM
Agarwal ShefaliChief Medical OfficerJun 26Sale16.151,80529,15178,611Jun 30 08:56 AM
TOMBESI PAOLOChief Financial OfficerJun 26Sale16.151,80529,15121,942Jun 30 08:57 AM
Ros MatthewSee RemarksJun 26Sale16.152,72844,05757,507Jun 30 08:54 AM
Ros MatthewSee RemarksJun 18Option Exercise9.47112,0031,060,669120,449Jun 22 07:31 PM
Bazemore Robert BPresident & CEOJun 18Option Exercise8.9810,00089,800264,371Jun 22 07:36 PM
Bazemore Robert BPresident & CEOJun 18Sale22.0020,000440,000244,371Jun 22 07:36 PM
Ros MatthewSee RemarksJun 18Sale21.24112,0032,378,44451,798Jun 22 07:31 PM
Beaulieu JosephCorporate ControllerMar 25Sale15.282123,2394,961Mar 26 09:11 PM
TOMBESI PAOLOChief Financial OfficerMar 25Sale15.281,24318,99315,437Mar 26 09:01 PM
Ros MatthewSee RemarksMar 25Sale15.281,24318,99351,798Mar 26 09:01 PM
Agarwal ShefaliChief Medical OfficerMar 25Sale15.281,24318,99371,991Mar 26 09:00 PM
Bazemore Robert BPresident & CEOMar 25Sale15.283,28550,195254,371Mar 26 09:00 PM
Allen Andrew RDirectorMar 16Option Exercise9.3312,500116,62512,500Mar 18 04:30 PM
Beaulieu JosephCorporate ControllerMar 03Sale22.1899622,0913,617Mar 05 06:52 PM
Agarwal ShefaliChief Medical OfficerJan 27Sale20.442,63053,75758,803Jan 27 09:19 PM
Bazemore Robert BPresident & CEOJan 27Sale20.446,074124,15384,668Jan 27 09:17 PM
Agarwal ShefaliChief Medical OfficerJan 24Sale24.641,84345,41261,433Jan 27 09:19 PM
Bazemore Robert BPresident & CEOJan 24Sale24.623,00273,90990,742Jan 27 09:17 PM
Ros MatthewSee RemarksJan 24Sale24.641,84745,51042,185Jan 27 09:18 PM
Beaulieu JosephCorporate ControllerJan 24Sale24.633308,1281,042Jan 27 09:16 PM